Literature DB >> 11207668

Acute opioid receptor desensitization and tolerance: is there a link?

S L Borgland1.   

Abstract

1. Morphine, used long-term for the treatment of pain, results in drug tolerance. The therapeutic benefits, as well as side effects, of morphine are mediated predominantly via activation of mu-opioid receptors. Although the underlying mechanisms for opioid tolerance remains unclear, early adaptive processes, such as acute receptor desensitization and receptor downregulation, have been suggested to be crucial to the development of opioid tolerance. 2. Other neuroadaptations resulting from chronic opioid use include upregulation of the cAMP pathway, an increase in the cAMP response element-binding protein and Fos-related antigens. However, the connection between upregulation of these cellular elements and the mechanism behind the behavioural phenomenon remains unclear. 3. Acute receptor desensitization is thought to occur via uncoupling of the receptor and G-protein, which is followed by internalization of the receptor from the cell membrane. This process occurs after a few minutes of agonist exposure. Receptor-G-protein uncoupling is mediated via phosphorylation of putative sites on the intracellular loops of activated receptors. 4. Acute desensitization and downregulation of receptors both result in a reduction of agonist efficacy. These events occur early in the cascade of cellular adaptation; however, it is uncertain whether these processes contribute to the long-term changes in receptor sensitivity that occur after repeated exposure to opioids. 5. Acute desensitization may, in fact, be a protective mechanism whereby cells adapt to avoid the development of physiological drug tolerance by rapidly attenuating receptor-mediated signalling. Those drugs that do not cause receptor internalization, such as morphine, may have higher propensities to develop tolerance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207668     DOI: 10.1046/j.1440-1681.2001.03418.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  25 in total

1.  Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies.

Authors:  Achla Gupta; Raphael Rozenfeld; Ivone Gomes; Kirsten M Raehal; Fabien M Décaillot; Laura M Bohn; Lakshmi A Devi
Journal:  J Biol Chem       Date:  2008-02-06       Impact factor: 5.157

2.  Lithium reverses the effect of opioids on eNOS/nitric oxide pathway in human umbilical vein endothelial cells.

Authors:  Sadaf Nezamoleslami; Mohammad Sheibani; Faiza Mumtaz; Jamileh Esmaeili; Hamed Shafaroodi; Ahmad Reza Dehpour
Journal:  Mol Biol Rep       Date:  2020-09-04       Impact factor: 2.316

3.  In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.

Authors:  Samuel Obeng; Yunyun Yuan; Abdulmajeed Jali; Dana E Selley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2018-03-09       Impact factor: 4.432

4.  [Opioid-induced analgesia and hyperalgesia].

Authors:  W Koppert
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

5.  Development of tolerance and sensitization to different opioid agonists in rats.

Authors:  Gisela Grecksch; Katharina Bartzsch; Antje Widera; Axel Becker; Volker Höllt; Thomas Koch
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

Review 6.  μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology.

Authors:  John Traynor
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

7.  Regulation of rat MOR-1 gene expression after chronic intracerebroventricular administration of morphine.

Authors:  Zhi-Ping Zhu; Ramesh B Badisa; Donald E Palm; Carl B Goodman
Journal:  Mol Med Rep       Date:  2011-11-15       Impact factor: 2.952

8.  Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies.

Authors:  In Park; Dongwon Kim; Jindeog Song; Chang Hoon In; Seung-Wei Jeong; Sang Hun Lee; Bumchan Min; Dongho Lee; Sun-Ok Kim
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

9.  Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice.

Authors:  Hans G Cruz; Frédérique Berton; Monica Sollini; Christophe Blanchet; Marco Pravetoni; Kevin Wickman; Christian Lüscher
Journal:  J Neurosci       Date:  2008-04-09       Impact factor: 6.167

10.  Silencing of P2Y2 receptor delays Ap4A-corneal re-epithelialization process.

Authors:  Almudena Crooke; Aránzazu Mediero; Ana Guzmán-Aránguez; Jesús Pintor
Journal:  Mol Vis       Date:  2009-06-11       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.